BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Radioligand Therapy Market Global and Regional Analysis.
According to this study the global Radioligand Therapy Market was valued at $9,754.9 million in 2020 and is expected to reach $16,658.4 million by 2031, witnessing a CAGR of 4.67% during the forecast period 2021-2031.
In the comprehensive study of the global radioligand therapy market, BIS Research extensively covers the following:
• Market numbers on micro-segments influencing the market
• Market share analysis of key market players
• Growth share analysis of companies
• Impact of COVID-19 on the global radioligand therapy market
• Growth analysis by indication, product, biomarker, and region
• Detailed company and product profiling for 16 companies
• Pipeline analysis for potential pipeline drugs
• Market scenario for radioligand therapy marketed products and potential pipeline products
• Drivers promoting the growth of the market
• Emerging opportunities in the radioligand therapy market
Besides these parameters, the study also encompasses the market growth drivers, market restraining factors, opportunities, competition mapping, and segmental analysis.
BIS Research study indicates that the growing prevalence of cancer, strategic initiatives by key market players, and the rise in microbial sequencing are the major factors anticipated to contribute to the growth of the global radioligand therapy market.
The detailed study is a compilation of 07 market data tables and 138 figures spread through 182 pages and in-depth TOC on “Global Radioligand Therapy Market – Analysis and Forecast, 2021-2031”
USP of the Report
This extensive report can help in the following ways:
• Aids in product development
• Helps in targeting a segment for launching and approval of a new product
• Offers go-to-market strategies for the different product categories
• Supports diversifying the product portfolio based on unmet needs
• Helps in analyzing technological substitutes and compares the specification
• Helps to adjust the pricing of upcoming products
• Assists in exploring the newer applications
• Supports in analyzing the competitors’ funding scenario
COVID-19 Impact on Global Radioligand Therapy Market
The global spread of COVID-19, caused by the novel coronavirus SARS-CoV-2, has resulted in a continuing pandemic threat to global health. Nuclear medicine techniques can be used for functional imaging of pathophysiological processes at the cellular level and for treatment approaches based on targeted delivery of therapeutic radionuclides. Ongoing development of radiolabeling methods has significantly improved the accessibility of radiopharmaceutical products for targeted radionuclide therapy, but their use for biosafety threats such as SARS-CoV-2 is restricted by the contagious nature of these agents.
Moreover, radioligand therapies rely on complex supply chains and advanced logistics. The lockdowns imposed by most countries and the closure of borders have generated shortages of radionuclides and other essential raw material supplies in many countries
Who should buy this report?
Manufacturers of radioligand therapy-approved products and potential pipeline products
Pharmaceutical and biotechnology companies
Research and academic institutions
Key Questions Answered in the Report:
• How is radioligand therapy revolutionizing oncology?
• What are the major market drivers, challenges, and opportunities in the global radioligand therapy market?
• What are the underlying structures resulting in the emerging trends within the global radioligand therapy market?
• How is the COVID-19 pandemic impacting the global radioligand therapy ecosystem?
• What are the key development strategies that the major players are implementing in order to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to the use of radioligand-targeted therapies?
• What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?
• How is each market segment expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Following are the segments:
o Products (Approved Products and Potential Pipeline)
o Indication (Prostate Cancer, Neuroendocrine Tumor (NETs), and Others)
o Biomarker (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor)
o Region (North America, Europe, Asia-Pacific, and Rest-of-the-World)
• What are the growth opportunities for the radioligand therapy companies in the region of their operation?
• Who are the leading players with significant offerings in the global radioligand therapy market?
• Which companies are anticipated to be highly disruptive in the future, and why?
Get FREE Sample Report – https://bisresearch.com/requestsample?id=1280type=download
The scope of the report exclusively covers manufacturers offering proprietary radioligand therapy for target indications such as prostate cancer and neuroendocrine tumors. The study considers products based on various radioisotopes underlying applications in oncology to detect biomarkers and treatment of cancers. Moreover, the study considers the generics sales of Zytiga.